Bicycle Therapeutics PLC Form 4 insider transactions

Alistair Milnes, Chief Operating Officer of Bicycle Therapeutics PLC, sold 967 ordinary shares to cover tax withholding obligations related to the vesting and settlement of RSUs on July 3, 2024.

Baker Bros. Advisors LP converted non-voting ordinary shares of Bicycle Therapeutics PLC into ordinary shares in the form of American Depositary Shares (ADS) on June 17, 2024.

Baker Bros. Advisors and affiliated entities increased their holdings in Bicycle Therapeutics through a private placement of non-voting ordinary shares.

Baker Bros. Advisors and related entities report changes in beneficial ownership of Bicycle Therapeutics plc stock and options due to director Felix J. Baker's equity grants.

Michael Charles Ferguson Hannay, Chief Product & Supply Chain Officer of Bicycle Therapeutics plc, sold 257 ordinary shares to cover tax withholding obligations related to the vesting and settlement of RSUs.

CEO of Bicycle Therapeutics, Kevin Lee, sold 3,158 ordinary shares to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).

Michael Skynner, Chief Technology Officer of Bicycle Therapeutics plc, sold 955 ordinary shares to cover tax withholding obligations related to the vesting and settlement of RSUs.

Alistair Milnes, Chief Operating Officer of Bicycle Therapeutics plc, sold 955 ordinary shares on April 3, 2024, to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).

Nicholas Keen, Chief Scientific Officer of Bicycle Therapeutics plc, sold 790 ordinary shares on April 3, 2024, to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).

Nigel Crockett, Chief Business Officer of Bicycle Therapeutics, sold 955 ordinary shares to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).

Travis Alvin Thompson, Chief Accounting Officer of Bicycle Therapeutics plc, sold 152 ordinary shares on April 3, 2024, to cover statutory tax withholding obligations related to the vesting and settlement of RSUs.

Michael Charles Ferguson Hannay, Chief Product & Supply Chain Officer at Bicycle Therapeutics, was granted stock options for 58,000 ordinary shares on March 19, 2024.